ERBB2 and metastatic neoplasm: Anti-HER2 therapy in any therapeutic stage (neoadjuvant, adjuvant, first line in metastatic disease) has shown increased efficiency in blocking these tyrosine kinase receptors, evidenced by the high percentage of complete pathological responses, as well as the considerable percentage (47%) of complete remissions and stationary disease, in relation to the HER2-positive patient group.